Ted Love, MD, Joins Gilead Sciences’ Board of Directors
02 February 2024 - 8:31AM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Ted
Love, MD, has been appointed to the company’s Board of
Directors.
Dr. Love is currently chair of the Board of Directors of the
Biotechnology Innovation Organization and serves on the Boards of
Directors of Royalty Pharma and Structure Therapeutics. Previously,
he was the President and Chief Executive Officer of Global Blood
Therapeutics, Inc. where he led the company from a pre-clinical
startup to a global commercial company with a focus on sickle cell
disease. Prior, he was Executive Vice President, Research and
Development and Technical Operations at Onyx Pharmaceuticals, Inc.;
President, Chief Executive Officer and Chairman of Nuvelo, Inc.;
and Senior Vice President, Development at Theravance Biopharma,
Inc. He began his biotech career at Genentech. Dr. Love earned his
MD from the Yale School of Medicine and completed a residency in
Internal Medicine and a fellowship in cardiology at Massachusetts
General Hospital.
Known for championing access to care, Dr. Love received the
William E. Proudford Sickle Cell Fund 2023 Distinguished Service
Award for addressing ongoing healthcare disparities facing the
sickle cell disease community. In 2023, he also earned the Spirit
of the Heart Health Equity Champion Award from the Association of
Black Cardiologists.
“We are delighted to welcome Ted Love to the Gilead Board of
Directors,” said Daniel O’Day, Chairman and Chief Executive Officer
of Gilead Sciences. “Ted is a highly respected executive leader
with decades of experience in the biopharma industry, most recently
as CEO of a global healthcare company. Ted also has a strong
scientific background, and his focus on access and inclusion aligns
perfectly with Gilead’s values. Ted will be a valuable addition to
the Gilead Board as we continue to expand our impact on patients
and communities worldwide.”
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis, COVID-19, and cancer. Gilead operates in more than
35 countries worldwide, with headquarters in Foster City,
California.
For more information about Gilead, please visit
the company’s website at www.gilead.com or follow Gilead on X
(@GileadSciences).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240201926422/en/
Jacquie Ross, Investors investor_relations@gilead.com
Ashleigh Koss, Media public_affairs@gilead.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024